El Halabi Maan, Bou Daher Halim, Rustom Luma Basma O, Marrache Majd, Ichkhanian Yervant, Kahil Karine, El Sayed Mazen, Sharara Ala I
Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Division of Gastroenterology, American University of Beirut Medical Center, Beirut, Lebanon.
Int J Clin Pract. 2019 Aug 27:e13409. doi: 10.1111/ijcp.13409.
Serum lipase is a rapid and reliable laboratory test central to diagnosing acute pancreatitis (AP). Routine use in the emergency department (ED) setting for all cases of abdominal pain or as part of a standard laboratory biochemical profile may lead to unnecessary expenses.
To examine the utility of serum lipase determination at a tertiary care centre ED.
Retrospective cross-sectional study of ED patients having serum lipase determination over a 12-month period. Electronic medical records were reviewed for indication and interpretation leading to additional diagnostic imaging, specialist consultation, interventions or hospital admission.
A total of 24 133 adult patients visited the ED during the study period: 4976 (20.6%) had serum lipase determination, 614 (12.4%) had abnormal lipase, 130 of which (21.1%) were above the diagnostic threshold for acutre pancreatitis (AP) (>3× ULN). A total of 75 patients had confirmed AP (0.3% of all adult ED visits). The positive and negative predictive values of serum lipase (>3× ULN) for AP were 43.6% and 99.6%, respectively. One thousand eight hundred and ninety patients (38.0%) had no abdominal pain on history or physical examination. In this group, the total charge associated with lipase determination was $51 030 with 251 (13.3%) elevated lipase values triggering cross-sectional abdominal imaging in 61 (24.3%) patients and unwarranted gastroenterology consultation in three (1.2%) for an additional charge of $28 975.
Serum lipase is widely overutilised in the emergency setting resulting in unnecessary expenses and investigations. Evidence-based review of clinical guidelines and more restrictive testing can result in substantial cost savings and improved patient care.
血清脂肪酶是诊断急性胰腺炎(AP)的一项快速且可靠的实验室检查。在急诊科(ED)将其常规用于所有腹痛病例或作为标准实验室生化检查项目的一部分,可能会导致不必要的费用。
探讨在三级医疗中心急诊科测定血清脂肪酶的实用性。
对在12个月期间测定血清脂肪酶的急诊科患者进行回顾性横断面研究。查阅电子病历,了解导致额外诊断性影像学检查、专科会诊、干预措施或住院治疗的指征及解读情况。
在研究期间,共有24133名成年患者就诊于急诊科:4976名(20.6%)进行了血清脂肪酶测定,614名(12.4%)脂肪酶异常,其中130名(21.1%)高于急性胰腺炎(AP)的诊断阈值(>3倍正常上限)。共有75名患者确诊为AP(占所有成年急诊科就诊患者的0.3%)。血清脂肪酶(>3倍正常上限)对AP的阳性预测值和阴性预测值分别为43.6%和99.6%。1890名患者(38.0%)在病史或体格检查中无腹痛。在该组中,与脂肪酶测定相关的总费用为51030美元,251名(13.3%)脂肪酶值升高,导致61名(24.3%)患者进行了腹部横断面成像检查,3名(1.2%)患者进行了不必要的胃肠病学会诊,额外费用为28975美元。
血清脂肪酶在急诊环境中被广泛过度使用,导致不必要的费用和检查。基于证据对临床指南进行审查并采用更严格的检测方法,可大幅节省成本并改善患者护理。